- Home
- URGN
URGN
UroGen Pharma Ltd.
as 11-03-2025 4:00pm EST
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Upcoming Earnings Alert:
Get ready for potential market movements as UroGen Pharma Ltd. URGN prepares to release earnings report on 06 Nov 2025.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | RA'ANANA |
| Market Cap: | 830.4M | IPO Year: | 2017 |
| Target Price: | $28.50 | AVG Volume (30 days): | 921.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.42 - $21.71 | Next Earning Date: | 11-06-2025 |
| Revenue: | $94,238,000 | Revenue Growth: | 10.85% |
| Revenue Growth (this year): | 36.41% | Revenue Growth (next year): | 118.04% |
Stock Insider Trading Activity of UroGen Pharma Ltd. (URGN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Degnan Chris | URGN | Chief Financial Officer | Oct 8 '25 | Sell | $16.85 | 2,203 | $37,120.55 | 2,280 | |
| Smith Jason Drew | URGN | General Counsel | Sep 8 '25 | Sell | $19.11 | 1,520 | $29,047.20 | 43,305 | |
| Schoenberg Mark | URGN | Chief Medical Officer | Sep 8 '25 | Sell | $19.11 | 871 | $16,644.81 | 149,025 | |
| Schoenberg Mark | URGN | Chief Medical Officer | Aug 11 '25 | Sell | $17.69 | 10,000 | $176,900.00 | 149,025 |
Latest UroGen Pharma Ltd. News
URGN Breaking Stock News: Dive into URGN Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
Adherex Technologies Inc. (FENC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
GlobeNewswire
4 days ago
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
Zacks
4 days ago
Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates
Zacks
5 days ago
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
GlobeNewswire
7 days ago
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
GlobeNewswire
2 months ago
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Insider Monkey
5 months ago
H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy
MT Newswires
5 months ago
HC Wainwright Upgrades UroGen Pharma to Buy From Neutral, $50 Price Target
Compare URGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "URGN UroGen Pharma Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.